These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31738157)

  • 21. Recent advances and patents in solid dispersion technology.
    Iqbal B; Ali A; Ali J; Baboota S; Gupta S; Dang S; Shadab M; Sahni JK
    Recent Pat Drug Deliv Formul; 2011 Sep; 5(3):244-64. PubMed ID: 21834778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems.
    Liptrott NJ; Giardiello M; McDonald TO; Rannard SP; Owen A
    J Nanobiotechnology; 2018 Mar; 16(1):22. PubMed ID: 29544545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged Release of Anti-Retroviral Efavirenz From System Using ZIF-8 as Carrier.
    Tabosa AÉGA; Ferreira AS; da Silva NM; da Silva Nascimento DDS; de Moura Ferraz LR; Silva JYR; Junior SA; da Silva RMF; Rolim LA; Rolim-Neto PJ
    Curr HIV Res; 2020; 18(6):396-404. PubMed ID: 32753016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
    Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti HIV nanoemulsion formulation: optimization and in vitro-in vivo evaluation.
    Kotta S; Khan AW; Ansari SH; Sharma RK; Ali J
    Int J Pharm; 2014 Feb; 462(1-2):129-34. PubMed ID: 24374067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticulate-based drug delivery systems for small molecule anti-diabetic drugs: An emerging paradigm for effective therapy.
    Uppal S; Italiya KS; Chitkara D; Mittal A
    Acta Biomater; 2018 Nov; 81():20-42. PubMed ID: 30268916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed surfactant based (SNEDDS) self-nanoemulsifying drug delivery system presenting efavirenz for enhancement of oral bioavailability.
    Senapati PC; Sahoo SK; Sahu AN
    Biomed Pharmacother; 2016 May; 80():42-51. PubMed ID: 27133038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanoparticles in Ocular Drug Delivery Systems for Topical Administration: Promises and Challenges.
    Almeida H; Amaral MH; Lobao P; Frigerio C; Sousa Lobo JM
    Curr Pharm Des; 2015; 21(36):5212-24. PubMed ID: 26412360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safe and Effective Delivery of Amphotericin B: A Survey of Patents.
    Kaur L; Abhijeet ; Jain SK
    Recent Pat Nanotechnol; 2017; 11(3):214-234. PubMed ID: 28056751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
    Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.
    Kekitiinwa A; Szubert AJ; Spyer M; Katuramu R; Musiime V; Mhute T; Bakeera-Kitaka S; Senfuma O; Walker AS; Gibb DM;
    Pediatr Infect Dis J; 2017 Jun; 36(6):588-594. PubMed ID: 28505015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanoscale Formulations and Diagnostics With Their Recent Trends: A Major Focus of Future Nanotechnology.
    Mukherjee B; Dutta L; Mondal L; Dey NS; Chakraborty S; Maji R; Shaw TK
    Curr Pharm Des; 2015; 21(36):5172-86. PubMed ID: 26412361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs.
    Banerjee S; Pillai J
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):499-515. PubMed ID: 31104522
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
    Vieira CS; Bahamondes MV; de Souza RM; Brito MB; Rocha Prandini TR; Amaral E; Bahamondes L; Duarte G; Quintana SM; Scaranari C; Ferriani RA
    J Acquir Immune Defic Syndr; 2014 Aug; 66(4):378-85. PubMed ID: 24798768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
    Robbins GK; De Gruttola V; Shafer RW; Smeaton LM; Snyder SW; Pettinelli C; Dubé MP; Fischl MA; Pollard RB; Delapenha R; Gedeon L; van der Horst C; Murphy RL; Becker MI; D'Aquila RT; Vella S; Merigan TC; Hirsch MS;
    N Engl J Med; 2003 Dec; 349(24):2293-303. PubMed ID: 14668455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.
    Nylén H; Habtewold A; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
    Medicine (Baltimore); 2016 Aug; 95(34):e4631. PubMed ID: 27559961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral bioavailability: issues and solutions via nanoformulations.
    Pathak K; Raghuvanshi S
    Clin Pharmacokinet; 2015 Apr; 54(4):325-57. PubMed ID: 25666353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural product-based nanoformulations for cancer therapy: Opportunities and challenges.
    Kashyap D; Tuli HS; Yerer MB; Sharma A; Sak K; Srivastava S; Pandey A; Garg VK; Sethi G; Bishayee A
    Semin Cancer Biol; 2021 Feb; 69():5-23. PubMed ID: 31421264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
    DiCenzo R; Forrest A; Squires KE; Hammer SM; Fischl MA; Wu H; Cha R; Morse GD;
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1929-35. PubMed ID: 12760869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.